Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.
Tanaka N, Kikuchi E, Shirotake S, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Ito Y, Kosaka T, Kodaira K, Oyama M, Miyajima A, Momma T, Nakagawa K, Ueno M, Oya M. Tanaka N, et al. Among authors: kanao k. Eur Urol. 2014 Jan;65(1):227-34. doi: 10.1016/j.eururo.2012.11.050. Epub 2012 Dec 1. Eur Urol. 2014. PMID: 23219372
The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Nakajima Y, Oya M. Tanaka N, et al. Among authors: kanao k. Urol Oncol. 2014 Jan;32(1):48.e19-26. doi: 10.1016/j.urolonc.2013.07.003. Epub 2013 Sep 18. Urol Oncol. 2014. PMID: 24055429
A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Oyama M, Momma T, Nakajima Y, Jinzaki M, Oya M. Tanaka N, et al. Among authors: kanao k. Ann Surg Oncol. 2014 Nov;21(12):4041-8. doi: 10.1245/s10434-014-3830-3. Epub 2014 Jun 10. Ann Surg Oncol. 2014. PMID: 24912614
Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M. Shirotake S, et al. Among authors: kanao k. J Urol. 2015 Apr;193(4):1122-8. doi: 10.1016/j.juro.2014.10.022. Epub 2014 Oct 13. J Urol. 2015. PMID: 25444957
Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.
Nishimoto K, Shirotake S, Miyama Y, Kaneko G, Kanao K, Igarashi D, Takahashi T, Umezawa Y, Yasuda M, Oyama M. Nishimoto K, et al. Among authors: kanao k. IJU Case Rep. 2022 Feb 18;5(3):149-152. doi: 10.1002/iju5.12422. eCollection 2022 May. IJU Case Rep. 2022. PMID: 35509782 Free PMC article.
153 results